HitGen Partner BioAge Launches Phase II Trial for BGE-102
CHENGDU, China, July 14, 2026 HitGen Inc. has announced that its partner BioAge Labs has dosed the first participant...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CHENGDU, China, July 14, 2026 HitGen Inc. has announced that its partner BioAge Labs has dosed the first participant...
SAN DIEGO, Calif., July 14, 2026 Atrium Therapeutics has achieved an important regulatory milestone after the U.S. Food and...
